Literature DB >> 6963825

Aetiology of sympathetic ophthalmitis.

N A Rao, V G Wong.   

Abstract

The aetiology of sympathetic ophthalmitis is still unknown. Recent investigations on patients and experimental studies on allergic uveitis in guinea-pigs suggest that sympathetic ophthalmitis may be due to delayed hypersensitivity to one of the retinal antigens associated with photoreceptor membranes (called the retinal 's' antigen). It is postulated that a penetrating injury causes a reversal of normal tolerance by introducing an adjuvant effect from bacterial or viral contamination along with the release of the intraocular antigen. The antigen then gains access to the regional lymphatics by way of the penetrating wound. A specific cell-mediated immune response is then initiated followed by the onset of sympathetic ophthalmitis.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6963825

Source DB:  PubMed          Journal:  Trans Ophthalmol Soc U K        ISSN: 0078-5334


  4 in total

Review 1.  Penetrating ocular injuries in previously injured blind eyes: should we consider primary enucleation?

Authors:  D A Hollander; B H Jeng; J M Stewart
Journal:  Br J Ophthalmol       Date:  2004-03       Impact factor: 4.638

2.  Classical pathology of sympathetic ophthalmia presented in a unique case.

Authors:  Shida Chen; Mary E Aronow; Charles Wang; Defen Shen; Chi-Chao Chan
Journal:  Open Ophthalmol J       Date:  2014-06-27

Review 3.  Sympathetic ophthalmia: A comprehensive update.

Authors:  Swapnil Parchand; Deepshikha Agrawal; Nikitha Ayyadurai; Aniruddha Agarwal; Anil Gangwe; Shashwat Behera; Priyavat Bhatia; Samyak Mulkutkar; Gulshan Barwar; Ramandeep Singh; Alok Sen; Manisha Agarwal
Journal:  Indian J Ophthalmol       Date:  2022-06       Impact factor: 2.969

4.  A penetrating ocular injury can affect the induction of anterior chamber-associated immune deviation.

Authors:  Fang Lei; Junfeng Zhang; Jinsong Zhang; Hao He; Ying Du; Peizeng Yang
Journal:  Mol Vis       Date:  2008-02-11       Impact factor: 2.367

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.